HCPCS Level II code Q5127 designates the 0.5 mg injection of pegfilgrastim-fpgk (brand name Stimufend), a biosimilar granulocyte colony-stimulating factor used to reduce the incidence of infection in patients receiving myelosuppressive chemotherapy. This code matters nationally as biosimilar biologics expand therapeutic options and affect coverage, utilization, and cost management across payers.

Key payers reviewed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for pegfilgrastim biosimilars, typical sites of service where Q5127 is billed, and payer coverage landscapes. The publication summarizes benchmarks for utilization and financial impacts where available, recent policy considerations around biosimilar substitution and billing, and coding clarifications relevant to administration of pegfilgrastim biosimilars.

The report is intended for revenue cycle managers, oncology clinicians, and policy analysts seeking a national-level reference on coding, clinical context, and payer patterns for biosimilar pegfilgrastim represented by HCPCS Level II code Q5127.